Fingolimod not checked

Novartis · FTY720

FollowEvery change as it happens, and a Monday email
Stage
in the US
Next date
None yet
 
Trials
3 active
8 in total · 2 in the EU
Targets
 

What this is

How it works
Sphingosine 1-phosphate Receptor Modulator FDA class
How it’s given
“Administrated orally once daily: 0.5 mg capsule for patients over 40 kg or 0.25 mg capsule for patients 40 kg or less.”In the company’s words, NCT01892722 on ClinicalTrials.gov
Tested for
Multiple Sclerosis (2 trials), Multiple Sclerosis (MS)
Main trialPhase 4
“The purpose of the study is to describe the safety profile of fingolimod in the Taiwanese multiple sclerosis population. This study aims to collect the safety data in patients newly initiated on fingolimod for one year.”In the company’s words, NCT04480853 on ClinicalTrials.gov
Other names
FTY720

Other drugs for Multiple Sclerosis

All 54 drugs for Multiple Sclerosis

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials8

TrialPhaseCompletesWhat it tests
Phase 4Active, not recruiting 15 Oct 2026 Safety and Efficacy Study of Fingolimod in Taiwanese Adults (≥ 20years) With Relapsing Remitting Multiple Sclerosis
Phase 3Active, not recruiting 14 Jul 2017 Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis
Phase 3Active, not recruiting 25 Mar 2026 Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis
Phase 4Completed 13 Jul 2015 Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
Phase 4Completed 5 Mar 2019 A Study of Immune Phenotype Biomarkers in Patients With Relapsing Multiple Sclerosis (RMS) After Treatment With 0.5mg Fingolimod
Phase 4Completed 24 Jan 2020 Long-term, Open-label, Multicenter Study Assessing Long-term Cardiovascular Risks
Phase 4Completed 25 Mar 2025 Study of Efficacy and Safety of Fingolimod (Gilenya) 0.5 mg in Chinese Patients With Relapsing Multiple Sclerosis (RMS) Patients
Phase 3Completed 19 Oct 2018 Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Fingolimod

Following is part of Solo: you see every change to Fingolimod the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in